IDE Antibodies

Santa Cruz Biotechnology features a diverse variety of IDE Antibodies for advanced research in protein function and regulation. Monoclonal IDE Antibodies are compatible with multiple techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Insulin-degrading enzyme (IDE) plays a crucial role in the metabolism of insulin and amyloid-beta peptides, making it significant in diabetes and Alzheimer's disease research. By regulating peptide levels, IDE contributes to maintaining glucose homeostasis and preventing toxic aggregate accumulation in the brain. Understanding IDE function is essential for developing therapeutic strategies targeting metabolic disorders and neurodegenerative diseases. Research has shown that IDE activity influences both insulin signaling pathways and amyloid-beta clearance mechanisms. Recent studies have highlighted IDE's potential as a therapeutic target for multiple pathological conditions. Investigating IDE's molecular interactions and regulatory mechanisms can provide valuable insights into disease progression and treatment approaches. IDE research using Santa Cruz Biotechnology monoclonal antibodies continues to advance scientific understanding of metabolic and neurodegenerative disorders, supporting breakthrough discoveries in medical research.